Tachykinin receptor 3: Difference between revisions
CSV import |
CSV import |
||
| Line 41: | Line 41: | ||
{{medicine-stub}} | {{medicine-stub}} | ||
{{No image}} | {{No image}} | ||
__NOINDEX__ | |||
Latest revision as of 01:35, 18 March 2025
Tachykinin receptor 3 (TACR3) is a protein that in humans is encoded by the TACR3 gene. It is a member of the tachykinin receptor subfamily of G protein-coupled receptors that respond to the neuropeptide neurokinin B. This receptor is predominantly expressed in the central nervous system and plays a role in neurological processes and pain perception.
Function[edit]
Tachykinin receptor 3 is involved in various biological functions primarily mediated by its high affinity for the peptide neurokinin B, which is a member of the tachykinin peptide family. Neurokinin B binds to TACR3 triggering a series of intracellular events that influence neuronal excitability, neurotransmitter release, and the modulation of pain signals and other sensory processes.
Clinical Significance[edit]
Mutations in the TACR3 gene are associated with hypogonadotropic hypogonadism, a condition characterized by delayed or absent puberty and an impaired sense of smell. This is due to the role of TACR3 in regulating the release of gonadotropin-releasing hormone (GnRH), which is critical for the initiation and maintenance of puberty.
Pharmacology[edit]
Agonists for TACR3 include neurokinin B and the synthetic peptide senktide, both of which mimic the natural ligand's action at the receptor. Conversely, SB-222200 acts as an antagonist and blocks the receptor's function, which can be useful in experimental models to understand the physiological and pathological roles of TACR3.
See also[edit]
